Marta Scorsetti 1 , Filippo Alongi , 1 , Antonella Fogliata 2 , Sara Pentimalli 1 , Pierina Navarria 1 , Francesca Lobefalo 1 , Carlos Garcia-Etienne 3 , Alessandro Clivio 2 , Luca Cozzi 2 , Pietro Mancosu 1 , Giorgia Nicolini 2 , Eugenio Vanetti 2 , Marco Eboli 3 , Carlo Rossetti 3 , Arianna Rubino 3 , Andrea Sagona 3 , Stefano Arcangeli 1 , Wolfgang Gatzemeier 3 , Giovanna Masci 4 , Rosalba Torrisi 4 , Alberto Testori 5 , Marco Alloisio 5 , Armando Santoro 4 , Corrado Tinterri 3
28 August 2012
To report results in terms of feasibility and early toxicity of hypofractionated simultaneous integrated boost (SIB) approach with Volumetric Modulated Arc Therapy (VMAT) as adjuvant treatment after breast-conserving surgery.
Between September 2010 and May 2011, 50 consecutive patients presenting early-stage breast cancer were submitted to adjuvant radiotherapy with SIB-VMAT approach using RapidArc in our Institution (Istituto Clinico Humanitas ICH). Three out of 50 patients were irradiated bilaterally (53 tumours in 50 patients). All patients were enrolled in a phase I-II trial approved by the ICH ethical committee. All 50 patients enrolled in the study underwent VMAT-SIB technique to irradiate the whole breast with concomitant boost irradiation of the tumor bed. Doses to whole breast and surgical bed were 40.5 Gy and 48 Gy respectively, delivered in 15 fractions over 3 weeks. Skin toxicities were recorded during and after treatment according to RTOG acute radiation morbidity scoring criteria with a median follow-up of 12 months (range 8–16). Cosmetic outcomes were assessed as excellent/good or fair/poor.
The median age of the population was 68 years (range 36–88). According to AJCC staging system, 38 breast lesions were classified as pT1, and 15 as pT2; 49 cases were assessed as N0 and 4 as N1. The maximum acute skin toxicity by the end of treatment was Grade 0 in 20/50 patients, Grade 1 in 32/50, Grade 2 in 0 and Grade 3 in 1/50 (one of the 3 cases of bilateral breast irradiation). No Grade 4 toxicities were observed. All Grade 1 toxicities had resolved within 3 weeks. No significant differences in cosmetic scores on baseline assessment vs. 3 months and 6 months after the treatment were observed: all patients were scored as excellent/good (50/50) compared with baseline; no fair/poor judgment was recorded. No other toxicities or local failures were recorded during follow-up.